Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Medicinova (MNOV) EBIT (2021 - 2025)

Medicinova (MNOV) has disclosed EBIT for 7 consecutive years, with $7.0 million as the latest value for Q4 2025.

  • On a quarterly basis, EBIT changed N/A to $7.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$3.2 million, a N/A change, with the full-year FY2025 number at -$2.5 million, up 80.13% from a year prior.
  • EBIT was $7.0 million for Q4 2025 at Medicinova, up from -$3.4 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $7.0 million in Q4 2025 to a low of -$3.6 million in Q2 2025.
  • A 5-year average of -$2.1 million and a median of -$3.2 million in 2024 define the central range for EBIT.
  • Peak YoY movement for EBIT: tumbled 1592.07% in 2022, then grew 13.1% in 2023.
  • Medicinova's EBIT stood at -$2.1 million in 2021, then crashed by 62.16% to -$3.4 million in 2022, then increased by 26.98% to -$2.5 million in 2023, then tumbled by 32.89% to -$3.3 million in 2024, then skyrocketed by 310.73% to $7.0 million in 2025.
  • Per Business Quant, the three most recent readings for MNOV's EBIT are $7.0 million (Q4 2025), -$3.4 million (Q3 2025), and -$3.6 million (Q2 2025).